We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: HIV
MedXY News
EnglishTag

HIV

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

M72/AS01E-4 Tuberculosis Vaccine: Promising Advances for HIV-Positive Populations in High-Burden Settings
Clinical UpdatesHIVimmunogenicity

M72/AS01E-4 Tuberculosis Vaccine: Promising Advances for HIV-Positive Populations in High-Burden Settings

By MedXY|Oct 1, 2025

A phase 2 trial in South Africa shows that the M72/AS01E-4 TB vaccine is safe and immunogenic for virally suppressed, ART-treated HIV-positive adolescents and adults, supporting its potential to address a key unmet clinical need.

Real-World Safety and Effectiveness of MVA-BN Vaccination Against Mpox: Evidence from German, Systematic Review, and Immunogenicity Cohorts
Clinical Updateseffectiveness
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
HIV

Real-World Safety and Effectiveness of MVA-BN Vaccination Against Mpox: Evidence from German, Systematic Review, and Immunogenicity Cohorts

By MedXY|Oct 1, 2025

MVA-BN vaccination is safe and effective against mpox in at-risk populations, but reduced protection is noted in people living with HIV. Dose strategies and patient immunological status may affect outcomes.

Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial
Clinical Updatesantiretroviral therapyclinical trial

Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial

By MedXY|Oct 1, 2025

The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.

Advances in Second-Line Antiretroviral Therapy for Children with HIV in Africa: Insights from the CHAPAS-4 Trial
Clinical Updatesantiretroviral therapyHIV

Advances in Second-Line Antiretroviral Therapy for Children with HIV in Africa: Insights from the CHAPAS-4 Trial

By MedXY|Sep 30, 2025

TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.

Novel HIV Peptides Identified During Treatment Interruption May Inform Next-Generation Therapeutic Strategies
Clinical UpdatesHIVVaccine

Novel HIV Peptides Identified During Treatment Interruption May Inform Next-Generation Therapeutic Strategies

By MedXY|Sep 30, 2025

Discovery of genetically conserved, mutation-intolerant HIV peptides in rebound virus during analytic treatment interruption highlights new avenues for mRNA vaccine development and functional HIV cure strategies.

Assessing Antibiotic Use During Pregnancy: Impact on Birth Outcomes in HIV Contexts
HIV/AIDSAntibioticsHIV

Assessing Antibiotic Use During Pregnancy: Impact on Birth Outcomes in HIV Contexts

By MedXY|Sep 30, 2025

A clinical study reveals that trimethoprim-sulfamethoxazole does not significantly improve infant birth weight or related outcomes in HIV-positive pregnancies.

Prev
2 / 2
12
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities